Q1 EPS Estimates for Globus Medical Raised by Zacks Research

Globus Medical, Inc. (NYSE:GMED) – Equities research analysts at Zacks Research boosted their Q1 2026 earnings estimates for Globus Medical in a note issued to investors on Thursday, April 23rd. Zacks Research analyst Team now anticipates that the medical device company will post earnings of $0.90 per share for the quarter, up from their prior forecast of $0.89. Zacks Research has a “Strong-Buy” rating on the stock. The consensus estimate for Globus Medical’s current full-year earnings is $4.46 per share. Zacks Research also issued estimates for Globus Medical’s Q1 2027 earnings at $1.09 EPS, Q4 2027 earnings at $1.25 EPS, FY2027 earnings at $4.70 EPS, Q1 2028 earnings at $1.22 EPS and FY2028 earnings at $5.27 EPS.

Globus Medical (NYSE:GMED) last issued its quarterly earnings results on Tuesday, February 24th. The medical device company reported $1.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.06 by $0.22. Globus Medical had a net margin of 18.30% and a return on equity of 12.57%. The company had revenue of $826.42 million during the quarter, compared to the consensus estimate of $803.29 million. During the same quarter in the previous year, the firm earned $0.84 earnings per share. The firm’s quarterly revenue was up 25.7% on a year-over-year basis.

A number of other research firms have also recently weighed in on GMED. Needham & Company LLC raised their price objective on shares of Globus Medical from $112.00 to $114.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. BTIG Research reissued a “neutral” rating on shares of Globus Medical in a report on Tuesday, December 30th. Canaccord Genuity Group raised their price objective on shares of Globus Medical from $105.00 to $112.00 and gave the stock a “buy” rating in a report on Friday, January 9th. Wall Street Zen raised shares of Globus Medical from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 3rd. Finally, TD Cowen raised shares of Globus Medical to a “strong-buy” rating in a report on Tuesday, January 27th. Three research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $104.36.

Globus Medical Trading Down 0.5%

GMED stock opened at $94.49 on Friday. Globus Medical has a twelve month low of $51.79 and a twelve month high of $101.40. The company’s 50 day moving average is $89.86 and its two-hundred day moving average is $84.52. The stock has a market cap of $12.78 billion, a P/E ratio of 23.98, a PEG ratio of 2.22 and a beta of 1.09.

Insider Buying and Selling

In related news, EVP Kelly Huller sold 20,000 shares of the company’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $94.50, for a total value of $1,890,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 18.51% of the stock is currently owned by company insiders.

Institutional Trading of Globus Medical

Institutional investors and hedge funds have recently bought and sold shares of the business. SBI Securities Co. Ltd. raised its position in Globus Medical by 98.2% in the 4th quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock valued at $29,000 after purchasing an additional 167 shares during the last quarter. Advisory Services Network LLC purchased a new stake in Globus Medical in the 3rd quarter valued at $26,000. EverSource Wealth Advisors LLC raised its position in Globus Medical by 74.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 197 shares during the last quarter. Larson Financial Group LLC raised its position in Globus Medical by 83.4% in the 4th quarter. Larson Financial Group LLC now owns 532 shares of the medical device company’s stock valued at $46,000 after purchasing an additional 242 shares during the last quarter. Finally, First Horizon Corp purchased a new stake in Globus Medical in the 3rd quarter valued at $31,000. Hedge funds and other institutional investors own 95.16% of the company’s stock.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.